symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LXRX,1.25,1.190114,2022340,306156240,0,0.96-3.79,-0.11,"Lexicon Pharmaceuticals, Inc.",USD,0001062822,US5288723027,528872302,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.lexpharma.com,"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.",Mr. Lonnel  Coats,Healthcare,US,135,281 863 3000,2445 Technology Forest Boulevard,The Woodlands,TX,77381,0.409343,2.62934,https://financialmodelingprep.com/image-stock/LXRX.png,2000-04-07,False,False,True,False,False
